GlassScriptPhysician profile
Molly Mae Warthan
NPI 1073773867
$5,282.29
in general payments reported to CMS, 2019-2025
30 companies · $786 in 2025
The $786 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $328 · 2021: $592 · 2022: $1,211 · 2023: $1,511 · 2024: $614 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,886 · Education: $24.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,886.44 |
| Education | $24.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,370.72 | 2019-2025 | |
| Merz North America, INC. | $674.84 | 2022-2023 | |
| Lilly USA, LLC | $636.23 | 2019-2024 | Olumiant, Taltz |
| Abbvie INC. | $469.79 | 2019-2024 | Skyrizi |
| Janssen Biotech, INC. | $382.08 | 2020-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $311.98 | 2019-2025 | Sotyktu |
| Amgen INC. | $169.02 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $167.58 | 2021-2025 | |
| Biofrontera INC. | $131.08 | 2020-2025 | Ameluz, Rhodoled Xl, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $95.32 | 2020-2025 | Aklief, Nemluvio |
| Revance Therapeutics, INC. | $89.26 | 2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $78.86 | 2020-2025 | Dupixent |
| Almirall LLC | $75.37 | 2021-2025 | Seysara, Klisyri |
| Ucb, INC. | $74.02 | 2024-2025 | Bimzelx |
| Solta Medical, A Division of Bausch Health US, LLC | $66.57 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $60.03 | 2023-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $59.90 | 2021-2023 | Odomzo, Blu-U |
| Incyte Corporation | $59.62 | 2022-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $46.93 | 2023-2024 | Zoryve |
| Genentech USA, INC. | $44.27 | 2020-2022 | |
| Convatec INC. | $36.02 | 2025 | |
| Bioventus LLC | $29.04 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.61 | 2022 | |
| Biowound Solutions, INC. | $23.24 | 2025 | Bio-Connekt |
| Dermira, INC. | $22.19 | 2020 | |
| Celgene Corporation | $22.04 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $16.66 | 2019 | |
| Medline Industries LP | $15.64 | 2019 | |
| Integra Lifesciences Corporation | $14.72 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Warthan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.